PennyIntel · Upcoming catalyst
ELDN catalyst watch: October 23 BESTOW presentation
Eledon Pharmaceuticals (Nasdaq: ELDN) has a specific research date ahead: an October 23 presentation on patient-reported outcomes from its Phase 2 BESTOW kidney-transplant trial. The comparison is tegoprubart versus tacrolimus. The useful question is what those patient assessments add to the kidney-function findings already reported. [1]
Dates and details
The presentation to follow
- When
- Friday, October 23, 4:40–4:50 p.m. Mountain Daylight Time; 6:40–6:50 p.m. Eastern.
- Where
- ASN Kidney Week in Denver, Mile High Ballroom 4A. Abstract FR-OR084.
- Presenter
- Andrew B. Adams, M.D., Ph.D., University of Minnesota Medical School.
The announced topic is patient-reported outcomes. Investors should check the actual presentation for the questionnaires used, comparison groups and statistical results. [1]
What the earlier extension data showed
On September 22, Eledon reported an approximately 13 mL/min/1.73 m² difference in mean estimated glomerular filtration rate at 24 months: 71 for tegoprubart versus 58 for tacrolimus. The company said 81 patients had been followed through 24 months. These were long-term extension findings; readers should distinguish that follow-up population from the original randomized population. [2]
That release also described plans to start the roughly 600-patient Phase 3 LEGACY study in the fourth quarter of 2026. Its proposed primary endpoint concerns efficacy failure at 12 months, including rejection, graft loss and death. The start of that study is a separate milestone from Friday's presentation. [2]
PennyIntel analysis
What would make the update useful?
A strong presentation would make the patient experience measurable: which outcomes changed, the size of the difference, how many patients answered and whether missing responses could affect the comparison. More detail on those questions would be more useful than a general statement that patients felt better.
For shareholders, the next practical checks are the release of the presentation materials, confirmation that LEGACY has started, and the resources required to execute the larger study. A conference appearance creates a date to investigate; the content and subsequent execution determine what has actually changed.
Stock Analysis showed ELDN at $2.13 with 151,928 shares traded at 9:45 a.m. Eastern on October 19, unchanged against its displayed previous close. This watch is based on the upcoming research event rather than a claimed breakout. [3]